Global Human Immunodeficiency Virus (HIV) Drugs Market [By Drug Class (Nucleoside reverse transcriptase inhibitors (NRTIs), Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Entry & Fusion Inhibitors, Integrase Inhibitors, Protease Inhibitors (PIs), and Combination Class Drugs); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)], and Geography - Trend, Analysis and Forecast Till 2025

Report Summary

Human Immune-deficiency Virus (HIV) is the most extensive and incurable disease, causes HIV infection and over time Acquired Immunodeficiency Syndrome (AIDS). There has been a significant rise in number of HIV population worldwide. According to the World Health Organization (WHO) 2013, HIV ranked 6th among the global deaths throughout the world, with approximately 1,776,270 deaths in 2009. HIV is the 2^ndmost common cause of death after cancer. According to the same reports in 2009, more than 1,780,000 global death case were filed. On the other side, surge in number of cases of infection transmission through infected blood and contaminated needles has been registered during past few years. For instance, according to WHO 2015, more than 150,000 HIV cases of infection due to contaminated needle were filed in India. Additionally, unprotected sex and breast milk by HIV infected mother are the most common route of HIV. This kind of infection affects a huge number of people across globally by decreasing the immunity of defence compared to infections.

However, HIV antivirals is the largest segment of drug in the HIV infection market. Pharmaceutical companies are continuously focusing on the research and development for developing new drugs in the term to cure HIV infection by improving the person’s lifestyle supressing infection virus throughout the life.

Increasing R&D in the area of HIV infection and growing demand for the drugs bolstering the HIV drugs market.

In the recent time, rising prevalence ofHIV infectionis on the huge surge. According to the World Health Organizations (WHO) 2015, globally around 37 million number of people were found to be infected with HIV. Thus, rising incidence of HIV infected people and the demand for the drugs to treat the disease are the major factors driving the global market. Additionally, Rise in the incidence of unprotected sex has led to increase in the prevalence of HIV/AIDS, further demanding cure drugs. Moreover, rising research and developments by the key players as well as investors to find the cure drugs for HIV infection and increasing government support for growing awareness regarding HIV and AIDS are further propelling HIV drugs market significantly.

However, unawareness regarding HIV infection in the developing and middle-income economies are the major restrains for the global market. Moreover, companies are facing challenges in penetrating the market due to low rate of deliberate screening for the disease in countries such as Africa, which further hinders the market growth.

Global Human Immunodeficiency Drugs (HIV) Market Taxonomy

The global Human Immunodeficiency (HIV) Drugs Market is segmented on the basis of Drug Class, Distribution channel, and geography.

On the basis of drug class, the global Human Immunodeficiency (HIV) drugs market is segmented into:

• Nucleoside reverse transcriptase inhibitors (NRTIs)
• Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs),
• Entry & Fusion Inhibitors
• Integrase Inhibitors
• Protease Inhibitors (PIs)
• Combination Class Drugs

On the basis of distribution channel, the global Human Immunodeficiency (HIV) drugs market is segmented into:

• Hospital Pharmacies
• 零售药店
• Online Pharmacies
• Others

Geographically, the global Human Immunodeficiency (HIV) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

North America to dominate the global market owing to well-maintained healthcare infrastructure and growing awareness regarding the HIV infection.

On the basis of geography, North America is the major dominating region in the global Human Immunodeficiency Virus (HIV) drugs market. The major market share in region is due to rising awareness about healthcare, well-established healthcare system, ample healthcare expenditure, rising government initiatives to control the spread of HIV, and higher HIV diagnosis & treatment rate. However, Asia-Pacific region is anticipated to grow with the highest share during forecast period, due to the presence large HIV patient pool, and ample growth opportunities in terms of unmet medical needs for management of HIV in the region. Moreover, increase in focus to find the possible cure for the infection & investment from key players in the region support the growth of the HIV drugs market in the Asia-Pacific region.

Key players in global Human Immunodeficiency (HIV) drugs market:

• Bristol-Myers Squibb Company
• ViiV Healthcare (Pfizer Inc.)
• GlaxoSmithKline plc
• Gilead Sciences Inc.
• Boehringer Ingelheim (C.H. Boehringer Sohn AG & Ko. KG)
• Hoffmann-La Roche AG
• Abbott Laboratories Inc.
• Janssen Therapeutics
• Merck & Co. Inc.
• Cipla Limited